Dec 11, 2025, 10:09 AM by

4D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced a collaboration with AMD and Oracle to advance predictive oncology and accelerate clinical trials. Using AMD EPYC™ CPUs on Oracle Cloud Infrastructure (OCI), 4D Path’s QPOR™ platform—a physics-informed, AI-driven, deterministic software engine—can convert routine biopsy images into interpretable biomarkers of tumor and immune response faster and at lower cost.

Dec 11, 2025, 09:22 AM by User Not Found

Bio-IT World | Historically, cancer treatment has relied on a one-size-fits-all approach known as the Standard of Care, where patients are treated based on population averages. But cancer is not a single disease; it’s thousands of distinct conditions, each driven by unique biology.

Dec 10, 2025, 09:25 AM by

Ansa Biotechnologies announced the appointment of Geoff Hamilton as Chief Financial Officer and Chief Business Officer.

Dec 10, 2025, 09:25 AM by

New integrations with industry leaders in EDC, eConsent, IRT/RTSM, eCOA, payments, and patient engagement expands Advarra's connected ecosystem, giving sponsors, CROs, and research sites secure, centralized access to critical study technologies

Dec 10, 2025, 09:25 AM by

Bio-IT World Conference & Expo, the premier global event uniting more than 2,900 biopharma, biomedical research, healthcare, informatics and technology leaders, returns to Boston May 19-21, 2026 to celebrate its 25th annual program with a direct impact on the future of precision medicine.

Dec 10, 2025, 09:25 AM by

New York Gastroenterology Associates, LLP , New York City’s leading independent gastroenterology practice, is working with Proscia®, a pathology AI company, to advance its standard of excellence.

Dec 8, 2025, 10:02 AM by User Not Found

Bio-IT World | Oxford Nanopore Technologies named a new CEO this morning, choosing an executive with extensive diagnostics experience. Francis Van Parys, currently CEO of Radiometer, will join Oxford Nanopore and the Board as an Executive Director on March 2, 2026.

Dec 8, 2025, 08:10 AM by

Landmark study from Inocras, Samsung Medical Center and Seoul St. Mary’s Hospital Researchers explores the whole genomes of 1,364 breast cancers, uncovering predictive biomarkers that link genomic signatures to potential treatment outcomes and support advancing precision oncology.

Dec 8, 2025, 08:10 AM by

Silverstone, UK, 8 December 2025: Lab Thread Ltd, a UK‐based life science software company, today announced the beta launch of its flagship unified lab software platform. Lab Thread is uniquely designed to provide an intuitive and adoptable platform with powerful collaborative features – helping to unite researchers, lab operations and scientific data from across diverse teams and advance scientific discovery.

Dec 5, 2025, 09:12 AM by

Dec 5, 2025, 09:12 AM by

Company’s third Human Factors Formative Study shows that 95% of participants prefer the Vaxess microarray patch to traditional injection devices

Dec 4, 2025, 08:38 AM by

PrecisionLife has announced new findings from the most detailed genetic analysis of myalgic encephalomyelitis ever conducted offering potential for faster and lower-risk routes to developing targeted treatments.

Dec 4, 2025, 08:38 AM by

4D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced that the company’s Q-Plasia OncoReader (QPOR™) platform has successfully predicted treatment response in patients with early-stage triple-negative breast cancer (TNBC) using digitized baseline biopsy images. Analysis conducted within the Translational Breast Cancer Research Consortium (TBCRC) 030 clinical trial represents the first demonstration of a statistical physics and tumor biology-based computational biomarker predicting post-treatment outcomes from pre-treatment tissue alone, without any clinical or molecular inputs.

Dec 4, 2025, 01:01 AM by User Not Found

Bio-IT World | Since artificial intelligence (AI) made its way into the medical field, foundation models—machine learning systems that are trained on broad data and adaptable to a wide range of downstream tasks—have become a focus. These foundation models are used to perform various medical tasks with minimal amounts of data. Of course, this means that these models require robust training, which poses a challenge for researchers.

Dec 3, 2025, 09:21 AM by

Compliance with independent security standards comes as Proscia accelerates digital pathology deployments at scale

Dec 3, 2025, 01:01 AM by User Not Found

Bio-IT World | As genetic testing becomes a routine part of modern medicine, researchers are grappling with an unintended consequence: a flood of never-before-seen genetic variants whose clinical significance is unknown. These variants of uncertain significance (VUS), now number in the tens of thousands, outpace the capacity of traditional scientific methods to determine whether they contribute to disease.

Dec 2, 2025, 01:01 AM by User Not Found

Bio-IT World | How depression gets treated in the next decade is poised for significant change thanks to encouraging developments in the use of psychedelics and dissociative compounds like ketamine to alleviate symptoms of the mood disorder. Scientific interest in psychedelic-based therapies has skyrocketed in recent years, driven by promising clinical trial outcomes, a flood of financial investment, and the urgent need for new treatments to counter a growing mental health crisis

Dec 1, 2025, 08:56 AM by

Nov 26, 2025, 08:05 AM by

Nov 25, 2025, 01:01 AM by User Not Found

Bio-IT World | Azalea Therapeutics will advance their Enveloped Delivery Vehicle (EDV) technology; Gate Biosciences will advance inflammatory and neurological disease treatments through the convenience of a pill; and more.